Monday, October 24, 2016

Protopam



pralidoxime chloride

Dosage Form: injection, powder, lyophilized, for solution
Protopam Chloride (pralidoxime chloride) for Injection

Rx only

Protopam Description


Chemical name: 2-formyl-1-methylpyridinium chloride oxime. Available in the United States as Protopam Chloride for Injection (Protopam), pralidoxime chloride is frequently referred to as 2-PAM Chloride.


Structural formula:


C7H9CIN2O     M.W. 172.61



Pralidoxime chloride occurs as an odorless, white, nonhygroscopic, crystalline powder which is soluble in water. Stable in air, it melts between 215º and 225º C, with decomposition.


The specific activity of the drug resides in the 2-formyl-1-methylpyridinium ion and is independent of the particular salt employed. The chloride is preferred because of physiologic compatibility, excellent water solubility at all temperatures, and high potency per gram, due to its low molecular weight.


Pralidoxime chloride is a cholinesterase reactivator.


Protopam for intravenous injection or infusion is prepared by cryo-desiccation. Each vial contains 1000 mg of sterile pralidoxime chloride, and sodium hydroxide to adjust pH, to be reconstituted with 20 mL of Sterile Water for Injection, USP. The pH of the reconstituted solution is 3.5 to 4.5. Intramuscular or subcutaneous injection may be used when intravenous injection is not feasible.



Protopam - Clinical Pharmacology


The principal action of pralidoxime chloride is to reactivate cholinesterase (mainly outside of the central nervous system) which has been inactivated by phosphorylation due to an organophosphate pesticide or related compound. The destruction of accumulated acetylcholine can then proceed, and neuromuscular junctions will again function normally. Pralidoxime chloride also slows the process of “aging” of phosphorylated cholinesterase to a nonreactivatable form, and detoxifies certain organophosphates by direct chemical reaction. The drug has its most critical effect in relieving paralysis of the muscles of respiration. Because pralidoxime chloride is less effective in relieving depression of the respiratory center, atropine is always required concomitantly to block the effect of accumulated acetylcholine at this site. Pralidoxime chloride relieves muscarinic signs and symptoms, salivation, bronchospasm, etc., but this action is relatively unimportant since atropine is adequate for this purpose.


Pralidoxime chloride has been studied in animals as an antidote against numerous organophosphate pesticides, chemicals, and drugs (see Animal Pharmacology and Toxicology). Regardless of whether or not animal studies suggest that the organophosphate poison to which a particular patient has been exposed is amenable to treatment with pralidoxime chloride, the use of pralidoxime chloride should, nevertheless, be considered in any life-threatening situation resulting from poisoning by these compounds, since the limited and arbitrary conditions of pharmacologic screening do not always accurately reflect the usefulness of pralidoxime chloride in the clinical situation.



Clinical Studies


There are no adequate and well controlled clinical studies that establish the effectiveness of pralidoxime chloride as a treatment for poisoning with organophosphates having anticholinesterase activity. However, its use has been considered to be successful against poisoning with numerous pesticides, chemicals, and drugs.



Pharmacokinetics


Animal studies suggest that the minimum therapeutic concentration of pralidoxime in plasma is 4 µg/mL; this level is reached in about 16 minutes after a single injection of 600 mg pralidoxime chloride. In one study of healthy adult volunteers and patients self-poisoned with organophosphate compounds, a single intramuscular injection of 1000 mg of pralidoxime chloride resulted in mean peak plasma levels of 7.5 ± 1.7 µg/mL and 9.9 ± 2.4 µg/mL, respectively. Time to reach the mean peak plasma levels in both groups was similar, 34 minutes in healthy adults and 33 minutes in poisoned patients. Mean half-life was about 3 hours in both groups.


Some evidence suggests that a loading dose followed by continuous intravenous infusion of pralidoxime chloride may maintain therapeutic levels longer than short intermittent infusion therapy. In a cross-over study of seven healthy adults (18 – 50 years) a short intravenous infusion dose of 16 mg/kg over 30 minutes was compared to an intravenous loading dose of 4 mg/kg over 15 minutes, followed by 3.2 mg/kg/hr for 3.75 hours (for a total dose of 16 mg/kg). Results showed that the mean time over which plasma levels were maintained above 4 µg/mL was prolonged in the volunteers who received a loading dose followed by continuous infusion as compared to those who received short infusion therapy (257.5 ± 50.5 min vs. 118.0 ± 52.1 min). Use of continuous intravenous infusion in adult patients with organophosphate poisoning has been described in several case reports, with and without loading doses. Infusion rates ranged from 400 – 600 mg/hr. In one case the blood levels were 11.6 – 13.7 µg/mL when given 400 mg/hr over 5 days (measured at 5, 10 and 18 hours). In another case following an initial loading dose of 1000 mg, blood levels were 11.79 µg/mL when given 500 mg/hr and 17.26 µg/mL when given 600 mg/hr. In the latter case the pralidoxime elimination half-life was 4 hours. In two other cases blood levels were not measured.


Pralidoxime chloride is distributed throughout the extracellular water; its apparent volume of distribution at steady state has been reported to range from 0.60 to 2.7 L/kg. Pralidoxime chloride is not bound to plasma protein.


Pralidoxime chloride is relatively short acting and repeated doses may be needed, unless continuous intravenous infusion is selected. Simulations suggest that after a dose of 1000 mg given intravenously, concentrations fall below 4 µg/mL in about 1.5 hours. The short duration of action of pralidoxime chloride and the necessity for repeated doses should be considered especially where there is any evidence of continuing absorption of the poison. The apparent half-life of pralidoxime is 74 to 77 minutes. The drug is rapidly excreted in the urine by renal tubular secretion, partly unchanged, and partly as a metabolite produced by the liver. After intramuscular administration of 1000 mg of pralidoxime chloride, the renal clearance has been reported to be 7.2 ± 2.9 mL/min/kg in healthy volunteers and 3.6 ± 1.5 mL/min/kg in organophosphate-poisoned patients.


In one study of 11 organophosphate-poisoned pediatric patients (age, 0.8 to 18 years), an intravenous loading dose of 15-50 mg/kg (mean 29 mg/kg) of pralidoxime chloride followed by a continuous infusion of 10-16 mg/kg/hr (mean 14 mg/kg/hr) over 12 to 43 hours (mean 27 ± 8 hours) resulted in an average steady state plasma concentration of 22.2 mg/L (6.9 to 47.4 mg/L) and an average body clearance of 0.88 L/kg/hr (0.28 to 2.20 L/kg/hr). After the continuous infusion was discontinued, determinations of the apparent volume of distribution and half-life ranged from 1.7 to 13.8 L/kg and from 2.4 to 5.3 hours, respectively.



Indications and Usage for Protopam


Protopam is indicated as an antidote:


  1. In the treatment of poisoning due to those pesticides and chemicals (e.g., nerve agents) of the organophosphate class which have anticholinesterase activity and

  2. In the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis.

The principal indications for the use of Protopam are muscle weakness and respiratory depression. In severe poisoning, respiratory depression may be due to muscle weakness.



Contraindications


There are no known absolute contraindications for the use of Protopam (see PRECAUTIONS, Drug Interactions, and DOSAGE AND ADMINISTRATION). Relative contraindications include known hypersensitivity to the drug and other situations in which the risk of its use clearly outweighs possible benefit.



Warnings


Protopam is not effective in the treatment of poisoning due to phosphorus, inorganic phosphates, or organophosphates not having anticholinesterase activity.


Protopam is not indicated as an antidote for intoxication by pesticides of the carbamate class since it may increase the toxicity of carbaryl.



Precautions



General


Protopam has been well tolerated in most cases, but it must be remembered that the desperate condition of the organophosphate-poisoned patient will generally mask such minor signs and symptoms as have been noted in normal subjects.


Intravenous administration of Protopam should be carried out slowly and, preferably, by continuous or intermittent infusion, since temporary worsening of cholinergic manifestations (i.e. tachycardia, cardiac arrest, laryngospasm, and muscle rigidity or paralysis) may occur if Protopam is infused too rapidly. The intermittent infusion rate should not exceed 200 mg/minute. If intravenous administration is not feasible, intramuscular or subcutaneous injection should be used (see DOSAGE AND ADMINISTRATION).


Protopam should be used with great caution in treating organophosphate overdosage in cases of myasthenia gravis since it may precipitate a myasthenic crisis.


Because pralidoxime is excreted in the urine, a decrease in renal function will result in increased blood levels of the drug. Thus, the dosage of Protopam should be reduced in the presence of renal insufficiency.



Laboratory Tests


Treatment of organophosphate poisoning should be instituted without waiting for the results of laboratory tests. Red blood cell, plasma cholinesterase, and urinary paranitrophenol measurements (in the case of parathion exposure) may be helpful in confirming the diagnosis and following the course of the illness, although such tests may be normal in the face of clinically significant organophosphate poisoning. A reduction in red blood cell cholinesterase concentration to below 50% of normal has been seen only with organophosphate ester poisoning.



Drug Interactions


When atropine and pralidoxime chloride are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. This is especially true if the total dose of atropine has been large and the administration of pralidoxime chloride has been delayed.


The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime chloride: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; morphine, theophylline, aminophylline, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning. Prolonged paralysis has been reported in patients when succinylcholine is given with drugs having anticholinesterase activity; therefore, it should be used with caution.



Carcinogenesis, Mutagenesis, Impairment of Fertility


Because pralidoxime chloride is indicated for short-term emergency use only, no investigations of its potential for carcinogenesis, mutagenesis, or impairment of fertility have been conducted by the manufacturer, or reported in the literature.



Pregnancy


Teratogenic Effects

Pregnancy Category C


Animal reproduction studies have not been conducted with pralidoxime chloride. It is also not known whether pralidoxime chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Pralidoxime chloride should be given to a pregnant woman only if clearly needed.



Nursing Mothers


It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when pralidoxime chloride is administered to a nursing woman.



Pediatric Use


There are no adequate and well-controlled clinical trials that establish the effectiveness of pralidoxime chloride in pediatric patients. Efficacy has been extrapolated from the adult population and is supported by nonclinical studies, pharmacokinetic studies in adults and experience in the pediatric population (see DOSAGE AND ADMINISTRATION). As in adults, laryngospasm, cardiac arrest, tachycardia, and muscle rigidity or paralysis have been reported following rapid intravenous injection. Muscle fasciculations, apnea, and convulsions have also been reported.



Geriatric Use


Clinical studies of Protopam did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.



Adverse Reactions


Forty to 60 minutes after intramuscular injection, mild to moderate pain may be experienced at the site of injection.


Pralidoxime chloride may cause blurred vision, diplopia and impaired accommodation, dizziness, headache, drowsiness, nausea, tachycardia, increased systolic and diastolic blood pressure, hyperventilation, and muscular weakness when given parenterally to normal volunteers who have not been exposed to anticholinesterase poisons. In patients, it is very difficult to differentiate the toxic effects produced by atropine or the organophosphate compounds from those of the drug.


Elevations in SGOT and/or SGPT enzyme levels were observed in 1 of 6 normal volunteers given 1200 mg of pralidoxime chloride intramuscularly, and in 4 of 6 volunteers given 1800 mg intramuscularly. Levels returned to normal in about 2 weeks. Transient elevations in creatine phosphokinase were observed in all normal volunteers given the drug.


When atropine and pralidoxime chloride are used together, the signs of atropinization may occur earlier than might be expected when atropine is used alone. This is especially true if the total dose of atropine has been large and the administration of pralidoxime chloride has been delayed. Excitement and manic behavior immediately following recovery of consciousness have been reported in several cases. However, similar behavior has occurred in cases of organophosphate poisoning that were not treated with pralidoxime chloride.



Drug Abuse and Dependence


Protopam is not subject to abuse and possesses no known potential for dependence.



Overdosage



Manifestations of Overdosage


Observed in normal subjects only: dizziness, blurred vision, diplopia, headache, impaired accommodation, nausea, slight tachycardia. In therapy it has been difficult to differentiate side effects due to the drug from those due to the effects of the poison.



Protopam Dosage and Administration



Organophosphate Poisoning


Treatment should include general supportive care, atropinization, and decontamination, in addition to the use of Protopam. Treatment is most effective if initiated immediately after poisoning. Administration of Protopam should be carried out slowly and, preferably, by infusion. If intravenous administration is not feasible, intramuscular or subcutaneous injection should be used. Generally, little is accomplished if Protopam is given more than 36 hours after termination of exposure to the poison. When the poison has been ingested, it is particularly important to take into account the likelihood of continuing absorption from the lower bowel since this constitutes new exposure and fatal relapses have been reported after initial improvement. In such cases, additional doses of Protopam may be needed every three to eight hours. In effect, the patient should be “titrated” with Protopam as long as signs of poisoning recur. As in all cases of organophosphate poisoning, care should be taken to keep the patient under observation for at least 48 to 72 hours.


If dermal exposure has occurred, clothing should be removed and the hair and skin washed thoroughly with sodium bicarbonate or alcohol as soon as possible.


Supportive care, including airway management, respiratory and cardiovascular support, correction of metabolic abnormalities, and seizure control, may be necessary in cases of severe organophosphate poisoning.


Atropine should be given as soon as possible after hypoxemia is improved. Atropine should not be given in the presence of significant hypoxia due to the risk of atropine-induced ventricular fibrillation. In adults, atropine may be given intravenously in doses of 2 to 4 mg. This should be repeated at 5- to 10-minute intervals until full atropinization (secretions are inhibited) or signs of atropine toxicity appear (delirium, hyperthermia, muscle twitching).


Some degree of atropinization should be maintained for at least 48 hours, and until any depressed blood cholinesterase activity is reversed.


Use of morphine, theophylline, aminophylline, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning (see PRECAUTIONS, Drug Interactions). Prolonged paralysis has been reported in patients when succinylcholine is given with drugs having anticholinesterase activity; therefore, it should be used with caution.


After the effects of atropine become apparent, Protopam may be administered.



Symptoms Of Nerve Agent And Insecticide Poisoning


Protopam dosing is based, in part, on the severity of symptoms of nerve agent intoxication. These symptoms include the following:


 


MILD symptoms:


  • Blurred vision and sore eyes

  • Teary eyes*

  • Runny nose*

  • Increased salivation such as sudden drooling*

  • Chest tightness or difficulty breathing

  • Tremors throughout the body or muscular twitching

  • Nausea and vomiting

  • Involuntary respiratory secretions

SEVERE symptoms:


  • Strange or confused behavior

  • Severe difficulty breathing or respiratory secretions

  • Severe muscular twitching and general weakness**

  • Involuntary urination and defecation*

  • Convulsions

  • Unconsciousness

Symptoms in INFANTS AND YOUNG CHILDREN:

* These symptoms are sometimes observed in healthy infants and young children. In this age group, these symptoms are less reliable than other symptoms listed. Symptoms must be considered collectively when nerve agent or pesticide exposure is known or suspected.


** Infants may become drowsy or unconscious, with muscle floppiness rather than muscle twitching, soon after exposure to nerve agents or pesticides.



ADULT DOSING


ADULT INTRAVENOUS DOSING:

Refer to the Preparation for Administration section for instructions on reconstitution and dilution of Protopam that result in a 10-20 mg/mL solution for intravenous infusion.


Inject an initial dose of 1000 to 2000 mg of Protopam, preferably as an infusion in 100 mL of normal saline, over a 15- to 30-minute period. If this is not practical or if pulmonary edema is present, the dose should be given slowly (over not less than five minutes) by intravenous injection, as a 50 mg/mL solution in water (e.g., 1000 mg in 20 mL). A second dose of 1000 to 2000 mg may be indicated after about one hour if muscle weakness has not been relieved. Additional doses may be given every 10-12 hours if muscle weakness persists.


Intravenous administration of Protopam should be carried out slowly and, preferably, by continuous or intermittent infusion, since temporary worsening of cholinergic manifestations (i.e. tachycardia, cardiac arrest, laryngospasm, and muscle rigidity or paralysis) may occur if Protopam is infused too rapidly. The intermittent infusion rate should not exceed 200 mg/minute. If intravenous administration is not feasible, intramuscular or subcutaneous injection should be used.


Evidence suggests that a loading dose followed by continuous intravenous infusion of Protopam may maintain therapeutic levels longer than traditional short intermittent infusion therapy (see Pharmacokinetics).


ADULT INTRAMUSCULAR DOSING:

Refer to the Preparation for Administration section for instructions on reconstitution of Protopam that result in an approximate 300 mg/mL solution for intramuscular administration.


Intramuscular dosing in adults should be based on the severity of clinical symptoms.


MILD SYMPTOMS


  • For treatment of mild symptoms, administer a 600 mg (2 mL) intramuscular dose of Protopam. Wait 15 minutes for Protopam to take effect.

  • If, after 15 minutes, mild symptoms persist, then administer a second 600 mg (2 mL) intramuscular dose of Protopam.

  • If, after an additional 15 minutes, mild symptoms continue to persist, a third 600 mg (2 mL) intramuscular dose of Protopam may be administered for a total cumulative dose of 1800 mg.

  • If at any time after the first dose, the patient develops severe symptoms, administer two additional 600 mg intramuscular doses in rapid succession for a total cumulative dose of 1800 mg of Protopam.

SEVERE SYMPTOMS


  • For treatment of severe symptoms, administer three 600 mg intramuscular doses (3 doses of 2 mL each) in rapid succession for a total dose of 1800 mg of Protopam.

PERSISTENT SYMPTOMS


  • If symptoms persist after administering the complete 1800 mg regimen (3 injections of 600 mg each), the series may be repeated beginning approximately 1 hour after administration of the last injection.


PEDIATRIC DOSING (FOR PATIENTS 16 YEARS AND UNDER)


PEDIATRIC INTRAVENOUS DOSING:

Refer to the Preparation for Administration section for instructions on reconstitution and dilution of Protopam that result in a 10-20 mg/mL solution for intravenous infusion.


Protopam can be given as intermittent intravenous infusions or as a loading dose followed by continuous intravenous infusion, depending upon the patient’s clinical condition. The specific dose given should depend upon the severity of the symptoms.  



Loading Dose Followed By Continuous Infusion


Administer a loading dose of 20-50 mg/kg (not to exceed 2000 mg/dose) over 15-30 minutes followed by a continuous infusion of 10-20 mg/kg/hour.



Intermittent Infusion Dosing


Administer an initial intermittent infusion of 20-50 mg/kg (not to exceed 2000 mg/dose) over 15-30 minutes. A second dose of 20-50 mg/kg may be indicated after about one hour if muscle weakness has not been relieved. Repeat dosing is permissible every 10-12 hours as needed.


If it is not practical to administer intermittent or continuous intravenous infusions, or if pulmonary edema is present, the 20-50 mg/kg dose should be given slowly (over not less than five minutes) by intravenous injection as a 50 mg/mL solution in water (see Preparation for Administration section). Additional doses may be given every 10-12 hours if muscle weakness persists.


PEDIATRIC INTRAMUSCULAR DOSING:

Refer to the Preparation for Administration section for instructions on reconstitution of Protopam that result in an approximate 300 mg/mL solution for intramuscular administration.


Intramuscular injections in children should be administered in the anterolateral aspect of the thigh to avoid the nerve, artery and vein, as well as the femur.


Pharmacokinetic modeling using published data from the scientific literature was conducted to derive intramuscular dosing recommendations in the pediatric population. The specific intramuscular dose of Protopam should depend upon the severity of the symptoms.


 


MILD SYMPTOMS


  • For treatment of mild symptoms, administer a weight-appropriate intramuscular dose (see Table 1 below) of Protopam. Wait 15 minutes for Protopam to take effect.

  • If, after 15 minutes, mild symptoms persist, then administer a second weight-appropriate intramuscular dose of Protopam.

  • If after an additional 15 minutes, mild symptoms continue to persist, a third weight-appropriate intramuscular dose of Protopam may be administered.

  • The three Protopam injections together are considered a single course of treatment, and the total amount of Protopam administered per course of treatment (i.e., 3 weight-appropriate injections) should not exceed the total amounts listed in Table 1 below.

  • If at any time after the first dose, the patient develops severe symptoms, administer two additional weight-appropriate intramuscular doses of Protopam in rapid succession.

SEVERE SYMPTOMS


  • For treatment of severe symptoms, administer the weight-appropriate intramuscular dose (see Table 1 below) of Protopam as three injections, in rapid succession, into the patient’s anterolateral thigh (see Table 1 below).

PERSISTENT SYMPTOMS


  • If symptoms persist after administering a complete course (3 injections of the weight-appropriate dose each), the series may be repeated beginning approximately 1 hour after administration of the last injection.













Table 1: Pediatric Intramuscular Dosing Recommendations*

*

Dosing is based on an approximate 300 mg/mL solution.

†

During the treatment for mild symptoms, if at any time after the first dose, the patient develops severe symptoms, administer two additional weight-appropriate intramuscular doses of Protopam in rapid succession.

‡

Additional courses of Protopam may be administered beginning one hour after the last injection. A single course consists of three separate, weight-appropriate injections, administered either with 15 minute inter-injection observation periods for patients with mild symptoms, or all in rapid succession for patients with severe symptoms.

§

Weight of 40 kg corresponds to approximately the 50th percentile for a 12 year old child per the weight-for-age percentile growth charts published by the Centers for Disease Control and Prevention in 2000.


Adult Dose Per Injection is 600 mg; Total Adult Dose per Three-Injection Course is 1800 mg.

Weight in kgDose Per Injection†Total Dose per Three-Injection Course‡
< 40kg15 mg/kg45 mg/kg
≥ 40 kg§Use Adult Dosing RecommendationsUse Adult Dosing Recommendations

Anticholinesterase Overdosage


As an antagonist to such anticholinesterases as neostigmine, pyridostigmine, and ambenonium, which are used in the treatment of myasthenia gravis, Protopam may be given in a dosage of 1000 to 2000 mg intravenously followed by increments of 250 mg every five minutes.



Preparation for Administration


Protopam is supplied as 1000 mg single-dose vials for injection.


For INTRAVENOUS infusion: Reconstitute a single Protopam 1000 mg vial by adding 20 mL of Sterile Water for Injection, USP, which results in a 50 mg/mL concentration.


The solution should be further diluted with Normal Saline for Injection, USP to achieve a concentration of 10 to 20 mg/mL (e.g. 1000 mg in 100 mL or 2000 mg in 100 mL).


For fluid restricted patients or for rapid administration (over at least 5 min), a maximum concentration of 50 mg/mL may be used.


For INTRAMUSCULAR injection: Reconstitute a single Protopam 1000 mg vial by adding 3.3 mL of Sterile Water for Injection, USP for an approximate concentration of 300 mg/mL.


Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.


Discard unused solution after a dose has been withdrawn.



How is Protopam Supplied


NDC 60977-141-01— Hospital Package: This contains six 20 mL vials of 1 g each of sterile Protopam Chloride (pralidoxime chloride) for Injection white to off-white porous cake*, without diluent or syringe.






*When necessary, sodium hydroxide is added during processing to adjust the pH.



Storage


Store at 20°-25°C (68°-77°F), excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].



ANIMAL PHARMACOLOGY AND TOXICOLOGY


The following table lists chemical and trade or generic names of pesticides, chemicals, and drugs against which Protopam (usually administered in conjunction with atropine) has been found to have antidotal activity on the basis of animal experiments. All compounds listed are organophosphates having anticholinesterase activity. A great many additional substances are in industrial use but have been omitted because of lack of specific information.






AAT—see PARATHION


AFLIX®—see FORMOTHION


ALKRON®—see PARATHION


AMERICAN CYANAMID 3422—see PARATHION


AMITON—diethyl-S-(2-diethylaminoethyl)phosphorothiolate


ANTHIO®—see FORMOTHION


APHAMITE—see PARATHION


ARMIN—ethyl-4-nitrophenylethylphosphonate


AZINPHOS-METHYL—dimethyl-S-[(4-oxo-1,2,3,-benzotriazin-3(4 H)-yl)methyl] phosphorodithioate


MORPHOTHION—dimethyl-S-2-keto-2-(N-morpholyl)ethylphosphorodithioate


NEGUVON®—see TRICHLOROFON


NIRAN®—see PARATHION


NITROSTIGMINE—see PARATHION


O,O-DIETHYL-O-p-NITROPHENYL PHOSPHOROTHIOATE—see PARATHION


O,O-DIETHYL-O-p-NITROPHENYLTHIO PHOSPHATE—see PARATHION


OR 1191—see PHOSPHAMIDON


OS 1836—see VINYLPHOS


OXYDEMETONMETHYL—dimethyl-S-2-(ethylsulfinyl) ethyl phosphorothiolate


PARAOXON—diethyl (4-nitrophenyl) phosphate


PARATHION—diethyl (4-nitrophenyl) phosphorothionate


PENPHOS—see PARATHION


PHENCAPTON—diethyl-S-(2,5-dichlorophenylmercaptomethyl) phosphorodithioate


PHOSDRIN®—see MEVINPHOS


PHOS-KIL—see PARATHION


PHOSPHAMIDON—1-chloro-1-diethylcarbamoyl-1-propen-2-yl-dimethylphosphate


PHOSPHOLINE IODIDE®—see echothiophate iodide


PHOSPHOROTHIOIC ACID, O,O-DIETHYL-O-p-NITROPHENYL ESTER—see PARATHION


PLANTHION—see PARATHION


QUELETOX—see FENTHION


RHODIATOX®—see PARATHION


RUELENE®—4-tert-butyl-2-chlorophenylmethyl-N-methylphosphoroamidate


SARIN—isopropyl-methylphosphonofluoridate


SHELL OS 1836—see VINYLPHOS


SHELL 2046—see MEVINPHOS


SNP—see PARATHION


SOMAN—pinacolyl-methylphosphonofluoridate


SYSTOX®—diethyl-(2-ethylmercaptoethyl) phosphorothionate


TEP—see TEPP


TEPP—tetraethylpyro phosphate


THIOPHOS® —see PARATHION


TIGUVON—see FENTHION


TRICHLOROFON—dimethyl-1-hydroxy-2,2,2-trichloroethylphosphonate


VAPONA®—see DICHLORVOS


VAPOPHOS—see PARATHION


VINYLPHOS—diethyl-2-chloro-vinylphosphate


Protopam appears to be ineffective, or marginally effective, against poisoning by:


  • CIODRIN® (alpha-methylbenzyl-3-[dimethoxyphosphinyloxy]-ciscrotonate)

  • DIMEFOX (tetramethylphosphorodiamidic fluoride)

  • DIMETHOATE (dimethyl-S-[N-methylcarbamoylmethyl]phosphorodithioate)

  • METHYL DIAZINON (dimethyl-[2-isopropyl-4-methylpyrimidyl]-phosphorothionate)

  • METHYL PHENCAPTON (dimethyl-S-[2,5-dichlorophenylmercaptomethyl]phosphorodithioate)

  • PHORATE (diethyl-S-ethylmercaptomethylphosphorodithioate)

  • SCHRADAN (octamethylpyrophosphoramide)

  • WEPSYN® (5-amino-1-[bis-(dimethylamino) phosphinyl]-3-phenyl-1,2,4-triazole).


Baxter and Protopam are trademarks of Baxter International, Inc., or its subsidiaries.


esi


Manufactured for


Baxter Healthcare Corporation


Deerfield, IL 60015 USA


By: Baxter Pharmaceutical Solutions LLC


Bloomington, IN 47403


For Product Inquiry 1 800 ANA DRUG (1-800-262-3784)


MLT00067,B



PACKAGE LABEL - Principal Display Panel


Container Label



NDC 60977-141-27


Protopam Chloride


(pralidoxime chloride) for injection


1 g Single Dose Vial


Rx only


FOR INTRAVENOUS INJECTION;


may be given subcutaneously or


intramuscularly if this route is not feasible.


Prepare injection by adding


20 mL of Sterile Water for


Injection, USP.


Usual Dosage: 1 g


See accompanying descriptive


literature. Discard unused solution


after a dose have been withdrawn.


Prepared by cryodesiccation.


esi


Mfd. for Baxter Healthcare Corp.


Deerfield, IL 60015 USA


by: Baxter Pharmaceutical Solutions, LLC


Bloomington, IN 47403


460-496-01


(01)00360977141275


3-942-233


Lot:


Exp:


Carton Label



NDC 60977-141-01


Protopam Chloride


(pralidoxime chloride) for injection


1 g


Rx only


6 x 1 g Single Dose Vials


FOR INTRAVENOUS INJECION;


may also be given by intramuscular or subcutaneous


injection if the intravenous route is not feasible.


esi


Manufactured for


Baxter Healthcare Corporation


Deerfield, IL 60015 USA


by: Baxter Pharmaceutical Solutions, LLC


Bloomington, IN 47403


Lot:


Exp:


NDC 60977-141-01


Protopam Chloride


(pralidoxime chloride) for injection


1 g


6 x 1 g Single Dose Vials


N3 60977 14101 5


Enclosed in this package are six vials, each containing 1 g of sterile


Protopam Chloride (pralidoxime chloride). When necessary, either 1N


hydrochloric acid or 1N sodium hydroxide may be added during


processing to adjust the pH. Prepare injection by adding 20 mL of


Sterile Water for Injection, USP (not supplied in this package).


Usual Dosage: 1 g


See accompanying descriptive literature.


Discard unused solution after a dose has been withdrawn.


Prepared by cryodesiccation.


Enclosed product circular for human use.


Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].


Baxter and Protopam are trademarks of Baxter International Inc. or its subsidiaries.


460-497-00


3-809-1808


NDC 60977-141-01


Protopam Chloride


(pralidoxime chloride) for injection


1 g


6 x 1 g Single Dose Vials


FOR INTRAVENOUS INJECTION;


may also be given by intramuscular


or subcutaneous injection


if the intravenous route is not feasible.


esi


Manufactured for


Baxter Healthcare Corporation


Deerfield, IL 60015 USA


by: Baxter Pharmaceutical Solutions LLC


Bloomington, IN 47403









Protopam CHLORIDE 
pralidoxime chloride  injection, powder, lyophilized, for solution










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)60977-141
Route of AdministrationINTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUSDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
PRALIDOXIME CHLORIDE (PRALIDOXIME)PRALIDOXIME CHLORIDE1 g






Inactive Ingredients
Ingredient NameStrength
SODIUM HYDROXIDE 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      














Packaging
#NDCPackage DescriptionMultilevel Packaging
160977-141-016 VIAL In 1 PACKAGEcontains a VIAL, SINGLE-DOSE (60977-141-27)
160977-141-271 VIAL In 1 VIAL, SINGLE-DOSEThis package is contained within the PACKAGE (60977-141-01)










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA01413412/06/2010


Labeler - Baxter Healthcare Corporation (005083209)









Establishment
NameAddressID/FEIOperations
BAXTER PHARMACEUTICAL SOLUTIONS, LLC604719430MANUFACTURE
Revised: 12/2010Baxter Healthcare Corporation

More Protopam resources


  • Protopam Side Effects (in more detail)
  • Protopam Use in Pregnancy & Breastfeeding
  • Protopam Drug Interactions
  • Protopam Support Group
  • 0 Reviews for Protopam - Add your own review/rating


Compare Protopam with other medications


  • Anticholinesterase Overdose
  • Nerve Agent Poisoning
  • Organophosphate Poisoning

Prorex



Generic Name: promethazine (Injection route, Intravenous route)

proe-METH-a-zeen

Injection route(Solution)

Promethazine hydrochloride injection should not be used in pediatric patients less than 2 yr of age because of the potential for fatal respiratory depression. Respiratory depression, including fatalities, have been reported with use of promethazine in pediatric patients less than 2 years of age in postmarketing experience. Exercise caution when administering promethazine hydrochloride injection to pediatric patients 2 years of age and older. Regardless of the administration route, promethazine hydrochloride injection can cause severe chemical irritation and damage to the tissue. Adverse reactions include burning, pain, thrombophlebitis, tissue necrosis, and gangrene, requiring surgical intervention, skin graft and/or amputation in some cases. Due to the risks of IV administration, the preferred route of administration is deep IM injection. SubQ injection is contraindicated .



Commonly used brand name(s)

In the U.S.


  • Antinaus 50

  • Phenergan

  • Promacot

  • Prorex

Available Dosage Forms:


  • Solution

Therapeutic Class: Gastrointestinal Agent


Pharmacologic Class: Antihistamine


Chemical Class: Aliphatic


Uses For Prorex


Promethazine injection is used to relieve or prevent some types of allergy or allergic reactions. It works by preventing the effects of a substance called histamine, which is produced by the body. Histamine can cause itching, sneezing, runny nose, and watery eyes. It can sometimes close up the bronchial tubes (air passages of the lungs) and make breathing difficult.


Promethazine is also used to prevent and control motion sickness, nausea, vomiting, and dizziness. In addition, it may be used to help people go to sleep and control their pain or anxiety before or after surgery or other procedures.


Promethazine may also be used for other conditions as determined by your doctor.


This medicine is only available with your doctor's prescription.


Before Using Prorex


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies have not been performed on the relationship of age to the effects of promethazine injection in the pediatric population. Use of promethazine injection is not recommended in children younger than 2 years of age because of the increased risk of respiratory depression. Caution should be used when this medicine is given to children 2 years of age and older.


Geriatric


Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of promethazine injection in the elderly. However, elderly patients may be more sensitive to the side effects of this medicine than in younger adults, and are more likely to have age-related heart or blood vessel disease or prostate problems, which may require an adjustment in the dose for patients receiving promethazine injection.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersCAnimal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.


  • Cisapride

  • Dronedarone

  • Grepafloxacin

  • Mesoridazine

  • Metoclopramide

  • Pimozide

  • Sparfloxacin

  • Thioridazine

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Alfuzosin

  • Amiodarone

  • Amitriptyline

  • Amoxapine

  • Apomorphine

  • Arsenic Trioxide

  • Asenapine

  • Astemizole

  • Azithromycin

  • Chloroquine

  • Chlorpromazine

  • Ciprofloxacin

  • Citalopram

  • Clarithromycin

  • Clomipramine

  • Clozapine

  • Crizotinib

  • Dasatinib

  • Desipramine

  • Disopyramide

  • Dofetilide

  • Dolasetron

  • Droperidol

  • Erythromycin

  • Fentanyl

  • Flecainide

  • Fluconazole

  • Gatifloxacin

  • Gemifloxacin

  • Granisetron

  • Halofantrine

  • Haloperidol

  • Hydromorphone

  • Ibutilide

  • Iloperidone

  • Imipramine

  • Isradipine

  • Lapatinib

  • Levofloxacin

  • Levorphanol

  • Lithium

  • Lopinavir

  • Lumefantrine

  • Mefloquine

  • Methadone

  • Metrizamide

  • Morphine

  • Morphine Sulfate Liposome

  • Moxifloxacin

  • Nilotinib

  • Norfloxacin

  • Nortriptyline

  • Octreotide

  • Ofloxacin

  • Ondansetron

  • Oxycodone

  • Paliperidone

  • Pazopanib

  • Pentamidine

  • Perflutren Lipid Microsphere

  • Posaconazole

  • Procainamide

  • Procarbazine

  • Prochlorperazine

  • Propafenone

  • Protriptyline

  • Quetiapine

  • Quinine

  • Ranolazine

  • Salmeterol

  • Saquinavir

  • Sodium Phosphate

  • Sodium Phosphate, Dibasic

  • Sodium Phosphate, Monobasic

  • Solifenacin

  • Sorafenib

  • Sotalol

  • Sunitinib

  • Tapentadol

  • Telavancin

  • Telithromycin

  • Terfenadine

  • Tetrabenazine

  • Toremifene

  • Tramadol

  • Trifluoperazine

  • Trimipramine

  • Vandetanib

  • Vardenafil

  • Vemurafenib

  • Voriconazole

  • Ziprasidone

  • Zolpidem

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Belladonna

  • Belladonna Alkaloids

  • Betel Nut

  • Evening Primrose

  • Meperidine

  • Midodrine

  • Phenylalanine

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Brain disease or injury or

  • Breathing or lung problems (e.g., asthma, COPD) or

  • Comatose state (unconscious) or

  • Reye's syndrome or

  • Sleep apnea, history of—Should not be used in patients with these conditions.

  • Bladder-neck blockage or

  • Bone marrow disease (e.g., agranulocytosis, leukopenia) or

  • Enlarged prostate or

  • Glaucoma, narrow-angle or

  • Heart or blood vessel disease or

  • Intestinal blockage or

  • Liver disease (including jaundice) or

  • Neuroleptic malignant syndrome, history of or

  • Respiratory depression (very slow breathing) or

  • Stomach ulcer or

  • Urinary tract blockage or difficult urination—Use with caution. May make these conditions worse.

  • Seizure disorders—This medicine may increase the chance of seizures especially in patients who are also using narcotic or anesthetic medicines.

Proper Use of promethazine

This section provides information on the proper use of a number of products that contain promethazine. It may not be specific to Prorex. Please read with care.


A nurse or other trained health professional will give you this medicine. This medicine is given as a shot into a muscle or into a vein.


Your doctor will give you a few doses of this medicine until your condition improves, and then switch you to an oral medicine that works the same way. If you have any concerns about this, talk to your doctor.


Precautions While Using Prorex


It is very important that your doctor check the progress of you or your child at regular visits to make sure this medicine is working properly. Blood tests may be needed to check for unwanted effects.


This medicine contains sodium metabisulfite. Make sure your doctor knows if you or your child have had an allergic reaction to sulfite in the past.


Check with your doctor right away if you or your child have burning, persistent or worsening pain at the injection site; or any involuntary muscle movements after receiving this medicine.


This medicine may affect blood sugar levels. If you or your child notice a change in the results of your blood or urine sugar tests or if you have any questions, check with your doctor.


This medicine will add to the effects of alcohol and other CNS depressants (medicines that make you drowsy or less alert). Some examples of CNS depressants are antihistamines or medicine for hay fever, other allergies, or colds; sedatives, tranquilizers, antidepressants, or sleeping medicine; prescription pain medicine or narcotics; medicine for seizures or barbiturates; muscle relaxants; or anesthetics, including some dental anesthetics. Check with your medical doctor or dentist before taking any of the above while you or your child are taking this medicine.


Check with your doctor right away if you or your child have pale or blue lips, fingernails, or skin; difficult or troubled breathing; irregular, fast, slow, or shallow breathing; or shortness of breath. These could be signs of a condition called respiratory depression.


This medicine may cause some people to become dizzy, lightheaded, drowsy, or less alert than they are normally. Even if taken at bedtime, it may cause some people to feel drowsy or less alert on arising. Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are not alert.


Promethazine can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. If you can, avoid people with infections. Check with your doctor immediately if you or your child think you are getting an infection or if you get a fever or chills, cough or hoarseness, lower back or side pain, or painful or difficult urination.


Check with your doctor right away if you or your child are having convulsions, difficulty in breathing, fast heartbeat, high fever, high or low blood pressure, increased sweating, loss of bladder control, severe muscle stiffness, unusually pale skin, or tiredness. These could be symptoms of a serious condition called neuroleptic malignant syndrome (NMS).


Check with your doctor right away if you or your child have pain or tenderness in the upper stomach; pale stools; dark urine; loss of appetite; nausea; unusual tiredness or weakness; or yellow eyes or skin. These could be symptoms of a liver problem.


Before you have any medical tests, tell the medical doctor in charge that you or your child are receiving this medicine. The results of some tests may be affected by this medicine.


This medicine may cause dryness of the mouth. For temporary relief, use sugarless candy or gum, melt bits of ice in your mouth, or use a saliva substitute. However, if your mouth continues to feel dry for more than 2 weeks, check with your medical doctor or dentist. Continuing dryness of the mouth may increase the chance of dental disease, including tooth decay, gum disease, and fungus infections.


This medicine may make your skin more sensitive to sunlight. Use a sunscreen when you are outdoors. Avoid sunlamps and tanning beds.


Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.


Prorex Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor or nurse immediately if any of the following side effects occur:


Rare
  • Convulsions (seizures)

  • difficult or unusually fast breathing

  • fast heartbeat or irregular pulse

  • high fever

  • high or low blood pressure

  • increased sweating

  • loss of bladder control

  • severe muscle stiffness

  • unusually pale skin

  • unusual tiredness or weakness

Incidence not known
  • Abdominal or stomach pain

  • black, tarry stools

  • blood in the urine

  • bloody nose

  • blurred vision

  • chest pain or discomfort

  • chills

  • clay-colored stools

  • cough or hoarseness

  • dark urine

  • decreased awareness or responsiveness

  • difficulty with speaking

  • dizziness

  • double vision

  • drooling

  • fast, pounding, or irregular heartbeat or pulse

  • fever with or without chills

  • fixed position of the eye

  • headache

  • heavier menstrual periods

  • increases and decreases in blood pressure

  • itching

  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs

  • lightheadedness, dizziness, or fainting

  • loss of appetite

  • loss of balance control

  • lower back or side pain

  • mimicry of speech or movements

  • muscle trembling, jerking, or stiffness

  • mutism

  • nausea

  • negativism

  • noisy breathing

  • painful or difficult urination

  • peculiar postures or movements, mannerisms, or grimacing

  • pinpoint red spots on the skin

  • restlessness

  • seeing double

  • seeing, hearing, or feeling things that are not there

  • seizures

  • severe sleepiness

  • shortness of breath

  • shuffling walk

  • skin rash

  • slow or irregular heartbeat

  • sore throat

  • sores, ulcers, or white spots on the lips or in the mouth

  • stiffness of the limbs

  • swollen glands

  • tenderness, pain, swelling, warmth, skin discoloration, and prominent superficial veins over the affected area

  • tightness in the chest

  • tremors

  • twisting movements of the body

  • uncontrolled movements, especially of the face, neck, and back

  • unpleasant breath odor

  • unusual bleeding or bruising

  • vomiting of blood

  • wheezing

  • yellow eyes or skin

Get emergency help immediately if any of the following symptoms of overdose occur:


Symptom of overdose
  • Abnormal movements

  • confusion as to time, place, or person

  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position

  • feeling of warmth

  • holding false beliefs that cannot be changed by fact

  • hyperexcitability

  • irregular, fast or slow, or shallow breathing

  • nightmares

  • pale or blue lips, fingernails, or skin

  • pupils of the eyes, large and not moving or responding to light

  • redness of the face, neck, arms, and occasionally, upper chest

  • sweating

  • troubled breathing

  • unusual excitement, nervousness, or restlessness

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


Incidence not known
  • Blistering, crusting, irritation, or reddening of the skin

  • continuing ringing or buzzing or other unexplained noise in the ears

  • discoloration of the skin

  • drowsiness

  • dry mouth

  • excitation

  • false or unusual sense of well-being

  • hearing loss

  • hives or welts

  • increased sensitivity of the skin to sunlight

  • lack of coordination

  • loss of strength or energy

  • muscle pain or weakness

  • nasal stuffiness

  • nervousness

  • severe sunburn

  • sleeplessness

  • trouble sleeping

  • unable to sleep

  • vomiting

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Prorex side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Prorex resources


  • Prorex Side Effects (in more detail)
  • Prorex Use in Pregnancy & Breastfeeding
  • Drug Images
  • Prorex Drug Interactions
  • Prorex Support Group
  • 67 Reviews for Prorex - Add your own review/rating


  • Promethazine Prescribing Information (FDA)

  • Phenadoz Prescribing Information (FDA)

  • Phenergan MedFacts Consumer Leaflet (Wolters Kluwer)

  • Phenergan Prescribing Information (FDA)

  • Phenergan Consumer Overview

  • Promethazine Hydrochloride Monograph (AHFS DI)

  • Promethegan Prescribing Information (FDA)



Compare Prorex with other medications


  • Allergic Reactions
  • Anaphylaxis
  • Hay Fever
  • Light Sedation
  • Motion Sickness
  • Nausea/Vomiting
  • Opiate Adjunct
  • Sedation
  • Urticaria
  • Vertigo

Maxzide-25


See also: Generic Maxzide


Maxzide-25 is a brand name of hydrochlorothiazide/triamterene, approved by the FDA in the following formulation(s):


MAXZIDE-25 (hydrochlorothiazide; triamterene - tablet; oral)



  • Manufacturer: MYLAN BERTEK

    Approval date: May 13, 1988

    Strength(s): 25MG;37.5MG [AB]

Has a generic version of Maxzide-25 been approved?


Yes. The following products are equivalent to Maxzide-25:


TRIAMTERENE AND HYDROCHLOROTHIAZIDE (hydrochlorothiazide; triamterene tablet; oral)



  • Manufacturer: APOTEX INC

    Approval date: May 5, 1998

    Strength(s): 25MG;37.5MG [AB]


  • Manufacturer: PLIVA

    Approval date: April 26, 1996

    Strength(s): 25MG;37.5MG [AB]


  • Manufacturer: SANDOZ

    Approval date: April 30, 1992

    Strength(s): 25MG;37.5MG [AB]


  • Manufacturer: WATSON LABS

    Approval date: September 23, 1993

    Strength(s): 25MG;37.5MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Maxzide-25. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Maxzide-25.

See also...

  • Maxzide-25 Consumer Information (Cerner Multum)
  • Triamterene/Hydrochlorothiazide Consumer Information (Wolters Kluwer)
  • Hydrochlorothiazide and triamterene Consumer Information (Cerner Multum)
  • Triamterene and hydrochlorothiazide Advanced Consumer Information (Micromedex)

Plan B


Pronunciation: LEE-voe-nor-JES-trel
Generic Name: Levonorgestrel
Brand Name: Plan B


Plan B is used for:

Preventing pregnancy after unprotected sexual intercourse or suspected birth control failure.


Plan B is a progestin. Exactly how it works is not known. It may prevent pregnancy by inhibiting ovulation, altering transport of sperm or eggs to prevent fertilization, or altering the lining of the uterus to prevent implantation should fertilization occur.


Do NOT use Plan B if:


  • you are allergic to any ingredient in Plan B

  • you are or suspect that you are pregnant

  • you have abnormal vaginal bleeding

  • you are taking nevirapine, rifampin, or St. John's wort

  • you have had a stroke or history of bleeding of the brain, known or suspected breast cancer, or a blood clotting disorder

Contact your doctor or health care provider right away if any of these apply to you.



Before using Plan B:


Some medical conditions may interact with Plan B. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are planning to become pregnant or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have a history of ectopic pregnancy or you are premenstrual

  • if you have diabetes

Some MEDICINES MAY INTERACT with Plan B. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Antifungals (eg, ketoconazole), aprepitant, barbiturates (eg, phenobarbital), bosentan, carbamazepine, felbamate, griseofulvin, HIV protease inhibitors (eg, indinavir), hydantoins (eg, phenytoin), modafinil, nevirapine, oxcarbazepine, penicillins (eg, amoxicillin), rifampin, rufinamide, St. John's wort, tetracyclines (eg, doxycycline), topiramate, or troglitazone because they may decrease Plan B's effectiveness

  • Anticoagulants (eg, warfarin) because their actions and the risk of their side effects may be increased or decreased by Plan B

  • Beta-adrenergic blockers (eg, metoprolol), corticosteroids (eg, prednisone), selegiline, theophylline, or troleandomycin because their actions and the risk of their side effects may be increased by Plan B

  • Lamotrigine because its effectiveness is decreased, and when levonorgestrel is stopped, toxic effects, such as nausea, dizziness, and vision problems may occur

  • Valproic acid because its effectiveness may be decreased by Plan B.

This may not be a complete list of all interactions that may occur. Ask your health care provider if Plan B may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Plan B:


Use Plan B as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • An extra patient leaflet is available with Plan B. Talk to your pharmacist if you have questions about this information.

  • Take Plan B as soon as possible after suspected birth control failure or after you have unprotected sexual intercourse. The first dose must be taken within 72 hours. Take the second tablet 12 hours after the first tablet. However, your doctor may instruct you to take Plan B in a different way. Follow the directions provided by your doctor.

  • Plan B can be used any time during the menstrual cycle.

  • If vomiting occurs within 1 hour after taking either tablet of Plan B, talk with your health care provider to discuss whether to repeat that dose.

  • A physical exam is not needed before taking Plan B. If you are unsure about your general health or pregnancy status, a follow-up physical or pelvic exam may be needed after taking Plan B.

  • If you miss a dose of Plan B, contact your doctor right away.

Ask your health care provider any questions you may have about how to use Plan B.



Important safety information:


  • Plan B may cause dizziness. This effect may be worse if you take it with alcohol or certain medicines. Use Plan B with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Plan B is an emergency contraceptive. It should not be used for routine birth control. If you have sexual intercourse after you take Plan B but before you have your next menstrual period, be sure to use an effective form of contraception, such as a diaphragm or condom.

  • Plan B does not protect against HIV infection and other sexually transmitted diseases.

  • Diabetes patients - Plan B may affect your blood sugar. Check blood sugar levels closely. Ask your doctor before you change the dose of your diabetes medicine.

  • Plan B should not be used in CHILDREN; safety and effectiveness in children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: Plan B will not end an existing pregnancy. Do not use Plan B if you are pregnant. Plan B is found in breast milk. If you are or will be breast-feeding while you use Plan B, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Plan B:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Breast tenderness; changes in menstrual flow; diarrhea; dizziness; headache; nausea; stomach pain; tiredness; vomiting.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); lower stomach pain; missed menstrual period; spotting instead of your usual period.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Plan B side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include nausea; vaginal bleeding; vomiting.


Proper storage of Plan B:

Store Plan B between 68 and 77 degrees F (20 and 25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Plan B out of the reach of children and away from pets.


General information:


  • If you have any questions about Plan B, please talk with your doctor, pharmacist, or other health care provider.

  • Plan B is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Plan B. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Plan B resources


  • Plan B Side Effects (in more detail)
  • Plan B Dosage
  • Plan B Use in Pregnancy & Breastfeeding
  • Plan B Drug Interactions
  • Plan B Support Group
  • 17 Reviews for Plan B - Add your own review/rating


  • Plan B Prescribing Information (FDA)

  • Plan B Advanced Consumer (Micromedex) - Includes Dosage Information

  • Plan B Consumer Overview

  • Levonorgestrel Professional Patient Advice (Wolters Kluwer)

  • Mirena Prescribing Information (FDA)

  • Mirena Consumer Overview

  • Mirena Advanced Consumer (Micromedex) - Includes Dosage Information

  • Next Choice Prescribing Information (FDA)

  • Plan B One-Step Advanced Consumer (Micromedex) - Includes Dosage Information

  • Plan B One-Step Consumer Overview



Compare Plan B with other medications


  • Emergency Contraception

Friday, October 21, 2016

Protonix





Dosage Form: injection, powder, for solution
FULL PRESCRIBING INFORMATION

Indications and Usage for Protonix



Gastroesophageal Reflux Disease Associated with a History of Erosive Esophagitis


Protonix I.V. for Injection is indicated for short-term treatment (7 to 10 days) of adult patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis.


Safety and efficacy of Protonix I.V. for Injection as a treatment of patients with GERD and a history of erosive esophagitis for more than 10 days have not been demonstrated.



Pathological Hypersecretion Including Zollinger-Ellison Syndrome


Protonix I.V. for Injection is indicated for the treatment of pathological hypersecretory conditions including Zollinger-Ellison Syndrome in adults.



Protonix Dosage and Administration


Parenteral drug products should be inspected visually for particulate matter and discoloration prior to and during administration whenever solution and container permit.


Parenteral routes of administration other than intravenous are not recommended.


Protonix I.V. for Injection may be administered intravenously through a dedicated line or through a Y-site. The intravenous line should be flushed before and after administration of Protonix I.V. for Injection with either 5% Dextrose Injection, USP, 0.9% Sodium Chloride Injection, USP, or Lactated Ringer’s Injection, USP. When administered through a Y-site, Protonix I.V. for Injection is compatible with the following solutions: 5% Dextrose Injection, USP, 0.9% Sodium Chloride Injection, USP, or Lactated Ringer's Injection, USP.


Midazolam HCl has been shown to be incompatible with Y-site administration of Protonix I.V. for Injection. Protonix I.V. for Injection may not be compatible with products containing zinc. When Protonix I.V. for Injection is administered through a Y-site, immediately stop use if precipitation or discoloration occurs.



Gastroesophageal Reflux Disease Associated With a History of Erosive Esophagitis


Recommended Dosage

The recommended adult dose is 40 mg pantoprazole given once daily by intravenous infusion for 7 to 10 days.


Treatment with Protonix® I.V. (pantoprazole sodium) for Injection should be discontinued as soon as the patient is able to receive treatment with Protonix Delayed-Release Tablets or Oral Suspension.


Administration and Preparation Instructions

Data on the safe and effective dosing for conditions other than those described [see Indications and Usage (1)] such as life-threatening upper gastrointestinal bleeds, are not available. Protonix I.V. 40 mg once daily does not raise gastric pH to levels sufficient to contribute to the treatment of such life-threatening conditions.



Fifteen Minute Infusion


Protonix I.V. for Injection should be reconstituted with 10 mL of 0.9% Sodium Chloride Injection, USP, and further diluted (admixed) with 100 mL of 5% Dextrose Injection, USP, 0.9% Sodium Chloride Injection, USP, or Lactated Ringer's Injection, USP, to a final concentration of approximately 0.4 mg/mL. The reconstituted solution may be stored for up to 6 hours at room temperature prior to further dilution. The admixed solution may be stored at room temperature and must be used within 24 hours from the time of initial reconstitution. Both the reconstituted solution and the admixed solution do not need to be protected from light.


Protonix I.V. for Injection admixtures should be administered intravenously over a period of approximately 15 minutes at a rate of approximately 7 mL/min.



Two Minute Infusion


Protonix I.V. for Injection should be reconstituted with 10 mL of 0.9% Sodium Chloride Injection, USP, to a final concentration of approximately 4 mg/mL. The reconstituted solution may be stored for up to 24 hours at room temperature prior to intravenous infusion and does not need to be protected from light. Protonix I.V. for Injection should be administered intravenously over a period of at least 2 minutes.



Pathological Hypersecretion Including Zollinger-Ellison Syndrome


Recommended Dosage

The dosage of Protonix I.V. for Injection in patients with pathological hypersecretory conditions including Zollinger-Ellison Syndrome varies with individual patients. The recommended adult dosage is 80 mg intravenously every 12 hours. The frequency of dosing can be adjusted to individual patient needs based on acid output measurements. In those patients who need a higher dosage, 80 mg intravenously every 8 hours is expected to maintain acid output below 10 mEq/h. Daily doses higher than 240 mg or administered for more than 6 days have not been studied [see Clinical Studies (14)]. Transition from oral to intravenous and from intravenous to oral formulations of gastric acid inhibitors should be performed in such a manner to ensure continuity of effect of suppression of acid secretion. Patients with Zollinger-Ellison Syndrome may be vulnerable to serious clinical complications of increased acid production even after a short period of loss of effective inhibition.


Administration and Preparation Instructions

Fifteen Minute Infusion


Each vial of Protonix I.V. for Injection should be reconstituted with 10 mL of 0.9% Sodium Chloride Injection, USP. The contents of the two vials should be combined and further diluted (admixed) with 80 mL of 5% Dextrose Injection, USP, 0.9% Sodium Chloride Injection, USP, or Lactated Ringer's Injection, USP, to a total volume of 100 mL with a final concentration of approximately 0.8 mg/mL. The reconstituted solution may be stored for up to 6 hours at room temperature prior to further dilution. The admixed solution may be stored at room temperature and must be used within 24 hours from the time of initial reconstitution. Both the reconstituted solution and the admixed solution do not need to be protected from light.


Protonix I.V. for Injection should be administered intravenously over a period of approximately 15 minutes at a rate of approximately 7 mL/min.



Two minute Infusion


Protonix I.V. for Injection should be reconstituted with 10 mL of 0.9% Sodium Chloride Injection, USP, per vial to a final concentration of approximately 4 mg/mL. The reconstituted solution may be stored for up to 24 hours at room temperature prior to intravenous infusion and does not need to be protected from light. The total volume from both vials should be administered intravenously over a period of at least 2 minutes.



Dosage Forms and Strengths


Protonix® I.V. (pantoprazole sodium) for Injection is supplied as a freeze-dried powder containing 40 mg of pantoprazole per vial.



Contraindications


Protonix is contraindicated in patients with known hypersensitivity reactions including anaphylaxis to the formulation [see Warnings and Precautions (5.2)] or any substituted benzimidazole.



Warnings and Precautions



Implications of Symptomatic Response


Symptomatic response to therapy with pantoprazole does not preclude the presence of gastric malignancy.



Hypersensitivity and Severe Skin Reactions


Anaphylaxis and other serious reactions such as erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis (TEN) have been reported with use of intravenous pantoprazole. These may require emergency medical treatment [see Adverse Reactions (6.2)].



Injection Site Reactions


Thrombophlebitis was associated with the administration of intravenous pantoprazole.



Potential for Exacerbation of Zinc Deficiency


Protonix contains edetate disodium (the salt form of EDTA), a chelator of metal ions including zinc. Therefore, zinc supplementation should be considered in patients treated with Protonix I.V. for Injection who are prone to zinc deficiency. Caution should be used when other EDTA containing products are also co-administered intravenously.



Bone Fracture


 Several published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to established treatment guidelines. (see Dosage And Administration and Adverse Reactions sections).



Hepatic Effects


Mild, transient transaminase elevations have been observed in clinical studies. The clinical significance of this finding in a large population of subjects administered intravenous pantoprazole is unknown. (See Adverse Reactions).



Hypomagnesemia


 Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, and in most cases after a year of therapy. Serious adverse events include tetany, arrhythmias, and seizures. In most patients, treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI.


 For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically. [see Adverse Reactions (6.2)].



Interference with Urine Screen for THC


May produce false-positive urine screen for THC (tetrahydrocannabinol).


[See Drug Interactions (7.4)].



Adverse Reactions


Worldwide, approximately 80,500 patients have been treated with pantoprazole in clinical trials involving various dosages and duration of treatment.



Clinical Trials Experience


Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.


Gastroesophageal Reflux Disease (GERD)

Safety in nine randomized comparative US clinical trials in patients with GERD included 1,473 patients on oral pantoprazole (20 mg or 40 mg), 299 patients on an H2-receptor antagonist, 46 patients on another proton pump inhibitor, and 82 patients on placebo. The most frequently occurring adverse reactions are listed in Table 1.


The number of patients treated in comparative studies with I.V. pantoprazole is limited; however, the adverse reactions seen were similar to those seen in the oral studies. Thrombophlebitis was the only new adverse reaction identified with I.V. pantoprazole.








































Table 1: Adverse Reactions Reported in Clinical Trials of Adult Patients with GERD at a Frequency of > 2%
 Protonix (n=1473) %Comparators (n=345) %Placebo (n=82) %
Headache12.212.88.5
Diarrhea8.89.64.9
Nausea7.05.29.8
Abdominal pain6.24.16.1
Vomiting4.33.52.4
Flatulence3.92.93.7
Dizziness3.02.91.2
Arthralgia2.81.41.2

Additional adverse reactions that were reported for Protonix in US clinical trials with a frequency of ≤ 2% are listed below by body system:


Body as a Whole: allergic reaction, fever, photosensitivity reaction, facial edema, thrombophlebitis (I.V. only)


Gastrointestinal: constipation, dry mouth, hepatitis


Hematologic: leukopenia (reported in ex-US clinical trials only), thrombocytopenia


Metabolic/Nutritional: elevated CPK (creatine phosphokinase), generalized edema, elevated triglycerides, liver function tests abnormal


Musculoskeletal: myalgia


Nervous: depression, vertigo


Skin and Appendages: urticaria, rash, pruritus


Special Senses: blurred vision


Zollinger-Ellison Syndrome

In clinical studies of Zollinger-Ellison Syndrome, adverse reactions reported in 35 patients taking Protonix 80 mg/day to 240 mg/day for up to 2 years were similar to those reported in adult patients with GERD.



Postmarketing Experience


The following adverse reactions have been identified during postapproval use of Protonix. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.


These adverse reactions are listed below by body system:


General Disorders and Administration Conditions: asthenia, fatigue, malaise


Immune System Disorders: anaphylaxis (including anaphylactic shock)


Investigations: weight changes


Skin and Subcutaneous Tissue Disorders: severe dermatologic reactions (some fatal), including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis (TEN), and angioedema (Quincke’s edema)


Musculoskeletal Disorders: rhabdomyolysis, bone fracture


Renal and Urinary Disorders: interstitial nephritis


Hepatobiliary Disorders: hepatocellular damage leading to jaundice and hepatic failure


Psychiatric Disorder: hallucinations, confusion, insomnia, somnolence


Metabolism and Nutritional Disorders: hyponatremia, hypomagnesemia



Drug Interactions



Interference with Antiretroviral Therapy


Concomitant use of atazanavir or nelfinavir with proton pump inhibitors is not recommended. Coadministration of atazanavir or nelfinavir with proton pump inhibitors is expected to substantially decrease atazanavir or nelfinavir plasma concentrations and may result in a loss of therapeutic effect and development of drug resistance.



Coumarin Anticoagulants


There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time.



Clopidogrel


Concomitant administration of pantoprazole and clopidogrel in healthy subjects had no clinically important effect on exposure to the active metabolite of clopidogrel or clopidogrel-induced platelet inhibition [see Clinical Pharmacology (12.3)]. No dose adjustment of clopidogrel is necessary when administered with an approved dose of Protonix.



Drugs for which Gastric pH Can Affect Bioavailability


Pantoprazole causes long-lasting inhibition of gastric acid secretion, therefore pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, and digoxin).



False Positive Urine Tests for THC


There have been reports of false positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving proton pump inhibitors including pantoprazole. An alternative confirmatory method should be considered to verify positive results.



USE IN SPECIFIC POPULATIONS



Pregnancy


Teratogenic Effects

Pregnancy Category B


Reproduction studies have been performed in rats at intravenous doses up to 20 mg/kg/day (4 times the recommended human dose based on body surface area) and rabbits at intravenous doses up to 15 mg/kg/day (6 times the recommended human dose based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to pantoprazole. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed [see Nonclinical Toxicology (13.2)].



Nursing Mothers


Pantoprazole and its metabolites are excreted in the milk of rats. Pantoprazole excretion in human milk has been detected in a study of a single nursing mother after a single 40 mg oral dose. The clinical relevance of this finding is not known. Many drugs which are excreted in human milk have a potential for serious adverse reactions in nursing infants. Based on the potential for tumorigenicity shown for pantoprazole in rodent carcinogenicity studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the benefit of the drug to the mother.



Pediatric Use


Safety and effectiveness of Protonix I.V. in pediatric patients have not been established.



Geriatric Use


No age-related differences in the safety profile of intravenous pantoprazole were seen in international trials involving 86 elderly (≥ 65 years old) and 200 younger (< 65 years old) patients with erosive esophagitis associated with GERD. Erosive esophagitis healing rates in the 107 elderly patients (≥ 65 years old) treated with oral pantoprazole in U.S. clinical trials were similar to those found in patients under the age of 65. The incidence rates of adverse events and laboratory abnormalities in patients aged 65 years and older were similar to those associated with patients younger than 65 years of age.



Gender


No gender-related differences in the safety profile of intravenous pantoprazole were seen in international trials involving 166 men and 120 women with erosive esophagitis associated with GERD. Erosive esophagitis healing rates in the 221 women treated with oral pantoprazole in U.S. clinical trials were similar to those found in men. The incidence rates of adverse reactions were also similar for men and women.



Hepatic Impairment


Doses higher than 40 mg/day have not been studied in patients with hepatic impairment [see Clinical Pharmacology (12.3)].



Overdosage


Experience in patients taking very high doses of pantoprazole (> 240 mg) is limited. Adverse events seen in spontaneous reports of overdose generally reflect the known safety profile of pantoprazole.


Pantoprazole is not removed by hemodialysis. In case of overdose, treatment should be symptomatic and supportive.


Single intravenous doses of pantoprazole at 378, 230, and 266 mg/kg (38, 46, and 177 times the recommended human dose based on body surface area) were lethal to mice, rats and dogs, respectively. The symptoms of acute toxicity were hypoactivity, ataxia, hunched sitting, limb-splay, lateral position, segregation, absence of ear reflex, and tremor.



Protonix Description


Therapeutic class: Proton Pump Inhibitor (PPI)


Route of administration: For Intravenous use only


The active ingredient in Protonix® I.V. (intravenous pantoprazole sodium) for Injection is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formula is C16H14F2N3NaO4S, with a molecular weight of 405.4. The structural formula is:



Pantoprazole sodium is a white to off-white crystalline powder and is racemic. Pantoprazole has weakly basic and acidic properties. Pantoprazole sodium is freely soluble in water, very slightly soluble in phosphate buffer at pH 7.4, and practically insoluble in n-hexane. The stability of the compound in aqueous solution is pH-dependent. The rate of degradation increases with decreasing pH. The reconstituted solution of Protonix I.V. for Injection is in the pH range 9.0 to 10.5.


Protonix I.V. for Injection is supplied as a freeze-dried powder in a clear glass vial fitted with a rubber stopper and crimp seal containing pantoprazole sodium, equivalent to 40 mg of pantoprazole, edetate disodium (1 mg), and sodium hydroxide to adjust pH.



Protonix - Clinical Pharmacology



Mechanism of Action


Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by covalently binding to the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. The binding to the (H+, K+)-ATPase results in a duration of antisecretory effect that persists longer than 24 hours for all doses tested (20 mg to 120 mg).



Pharmacodynamics


Antisecretory Activity

The magnitude and time course for inhibition of pentagastrin-stimulated acid output (PSAO) by single doses (20 to 120 mg) of Protonix I.V. for Injection were assessed in a single-dose, open-label, placebo-controlled, dose-response study. The results of this study are shown in Table 2. Healthy subjects received a continuous infusion for 25 hours of pentagastrin (PG) at 1 mcg/kg/h, a dose known to produce submaximal gastric acid secretion. The placebo group showed a sustained, continuous acid output for 25 hours, validating the reliability of the testing model. Protonix I.V. for Injection had an onset of antisecretory activity within 15 to 30 minutes of administration. Doses of 20 to 80 mg of Protonix I.V. for Injection substantially reduced the 24-hour cumulative PSAO in a dose-dependent manner, despite a short plasma elimination half-life. Complete suppression of PSAO was achieved with 80 mg within approximately 2 hours and no further significant suppression was seen with 120 mg. The duration of action of Protonix I.V. for Injection was 24 hours.






















































Table 2: Gastric Acid Output (mEq/hr, Mean ± SD) and Percent Inhibitiona (Mean ± SD) of Pentagastrin-Stimulated Acid Output Over 24 Hours Following a Single Dose of Protonix I.V. for Injectionb in Healthy Subjects
 ------2 hours------------4 hours------------12 hours------------24 hours------
Treatment DoseAcid Output% InhibitionAcid Output% InhibitionAcid Output% InhibitionAcid Output% Inhibition
0 mg (Placebo, n=4)39 ± 21NA26 ± 14NA32 ± 20NA38 ± 24NA
20mg (n=4-6)13 ± 1847 ± 276 ± 883 ± 2120 ± 2054 ± 4430 ± 2345 ± 43
40 mg

(n=8)
5 ± 582 ± 114 ± 490 ± 1111 ± 1081 ± 1316 ± 1252 ± 36
80 mg

(n=8)
0.1 ± 0.296 ± 60.3 ± 0.499 ± 12 ± 290 ± 77 ± 463 ± 18

a: Compared to individual subject baseline prior to treatment with Protonix I.V. for Injection. NA = not applicable.


b: Inhibition of gastric acid output and the percent inhibition of stimulated acid output in response to Protonix I.V. for Injection may be higher after repeated doses.


In one study of gastric pH in healthy subjects, pantoprazole was administered orally (40 mg enteric coated tablets) or intravenously (40 mg) once daily for 5 days and pH was measured for 24 hours following the fifth dose. The outcome measure was median percent of time that pH was ≥ 4 and the results were similar for intravenous and oral medications; however, the clinical significance of this parameter is unknown.


Serum Gastrin Effects

Serum gastrin concentrations were assessed in two placebo-controlled studies.


In a 5-day study of oral pantoprazole with 40 and 60 mg doses in healthy subjects, following the last dose on day 5, median 24-hour serum gastrin concentrations were elevated by 3-4 fold compared to placebo in both 40 and 60 mg dose groups. However, by 24 hours following the last dose, median serum gastrin concentrations for both groups returned to normal levels.


In another placebo-controlled, 7-day study of 40 mg intravenous or oral pantoprazole in patients with GERD and a history of erosive esophagitis, the mean serum gastrin concentration increased approximately 50% from baseline and as compared with placebo, but remained within the normal range.


During 6 days of repeated administration of Protonix I.V. for Injection in patients with Zollinger-Ellison Syndrome, consistent changes of serum gastrin concentrations from baseline were not observed.


Enterochromaffin-Like (ECL) Cell Effects

There are no data available on the effects of intravenous pantoprazole on ECL cells.


In a nonclinical study in Sprague-Dawley rats, lifetime exposure (24 months) to pantoprazole at doses of 0.5 to 200 mg/kg/day resulted in dose-related increases in gastric ECL-cell proliferation and gastric neuroendocrine (NE)-cell tumors. Gastric NE-cell tumors in rats may result from chronic elevation of serum gastrin concentrations. The high density of ECL cells in the rat stomach makes this species highly susceptible to the proliferative effects of elevated gastrin concentrations produced by proton pump inhibitors. However, there were no observed elevations in serum gastrin following the administration of pantoprazole at a dose of 0.5 mg/kg/day. In a separate study, a gastric NE-cell tumor without concomitant ECL-cell proliferative changes was observed in 1 female rat following 12 months of dosing with pantoprazole at 5 mg/kg/day and a 9 month off-dose recovery [see Nonclinical Toxicology (13.1)].



Pharmacokinetics


Pantoprazole peak serum concentration (Cmax) and area under the serum concentration-time curve (AUC) increase in a manner proportional to intravenous doses from 10 mg to 80 mg. Pantoprazole does not accumulate and its pharmacokinetics are unaltered with multiple daily dosing. Following the administration of Protonix I.V. for Injection, the serum concentration of pantoprazole declines biexponentially with a terminal elimination half-life of approximately one hour. In CYP2C19 extensive metabolizers [see Clinical Pharmacology (12.5)] with normal liver function receiving a 40 mg dose of Protonix I.V. for Injection by constant rate over 15 minutes, the peak concentration (Cmax) is 5.52 ±1.42 mcg/mL and the total area under the plasma concentration versus time curve (AUC) is 5.4 ±1.5 mcg• hr/mL. The total clearance is 7.6-14.0 L/h.


Distribution

The apparent volume of distribution of pantoprazole is approximately 11.0-23.6 L, distributing mainly in extracellular fluid. The serum protein binding of pantoprazole is about 98%, primarily to albumin.


Metabolism

Pantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. Pantoprazole metabolism is independent of the route of administration (intravenous or oral). The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity. CYP2C19 displays a known genetic polymorphism due to its deficiency in some sub-populations (e.g., 3% of Caucasians and African-Americans and 17-23% of Asians). Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10.0 hours, they still have minimal accumulation (≤ 23%) with once daily dosing.


Excretion

After administration of a single intravenous dose of 14C-labeled pantoprazole to healthy, extensive CYP2C19 metabolizers, approximately 71% of the dose was excreted in the urine with 18% excreted in the feces through biliary excretion. There was no renal excretion of unchanged pantoprazole.


Geriatric

After repeated I.V. administration in elderly subjects (65 to 76 years of age), pantoprazole AUC and elimination half-life values were similar to those observed in younger subjects. No dosage adjustment is recommended for elderly patients.


Gender

After oral administration there is a modest increase in pantoprazole AUC and Cmax in women compared to men. However, weight-normalized clearance values are similar in women and men. No dosage adjustment is warranted based on gender.


Renal Impairment

In patients with severe renal impairment, pharmacokinetic parameters for pantoprazole were similar to those of healthy subjects. No dosage adjustment is necessary in patients with renal impairment or in patients undergoing hemodialysis.


Hepatic Impairment

In patients with mild to severe hepatic impairment (Child-Pugh A to C cirrhosis), maximum pantoprazole concentrations increased only slightly (1.5-fold) relative to healthy subjects when pantoprazole was administered orally. Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted. These pharmacokinetic changes in hepatic-impaired patients result in minimal drug accumulation following once-daily, multiple-dose administration. No dosage adjustment is needed in patients with mild to severe hepatic impairment. Doses higher than 40 mg/day have not been studied in hepatically impaired patients.


Drug-Drug Interactions

Pantoprazole is metabolized mainly by CYP2C19 and to minor extents by CYPs 3A4, 2D6 and 2C9. In in vivo drug-drug interaction studies with CYP2C19 substrates (diazepam [also a CYP3A4 substrate] and phenytoin [also a CYP3A4 inducer]), nifedipine, midazolam, and clarithromycin (CYP3A4 substrates), metoprolol (a CYP2D6 substrate), diclofenac, naproxen and piroxicam (CYP2C9 substrates) and theophylline (a CYP1A2 substrate) in healthy subjects, the pharmacokinetics of pantoprazole were not significantly altered.


Clopidogrel is metabolized to its active metabolite in part by CYP2C19. In a crossover clinical study, 66 healthy subjects were administered clopidogrel (300 mg loading dose followed by 75 mg per day) alone and with pantoprazole (80 mg at the same time as clopidogrel) for 5 days. On Day 5, the mean AUC of the active metabolite of clopidogrel was reduced by approximately 14% (geometric mean ratio was 86%, with 90% CI of 79 to 93%) when pantoprazole was coadministered with clopidogrel as compared to clopidogrel administered alone. Pharmacodynamic parameters were also measured and demonstrated that the change in inhibition of platelet aggregation (induced by 5 µM ADP) was correlated with the change in the exposure to clopidogrel active metabolite. The clinical significance of this finding is not clear.


In vivo studies also suggest that pantoprazole does not significantly affect the kinetics of other drugs (cisapride, theophylline, diazepam [and its active metabolite, desmethyldiazepam], phenytoin, warfarin, metoprolol, nifedipine, carbamazepine, midazolam, clarithromycin, naproxen, piroxicam and oral contraceptives [levonorgestrel/ethinyl estradiol]). Dosage adjustment of such drugs is not necessary when they are co-administered with pantoprazole. In other in vivo studies, digoxin, ethanol, glyburide, antipyrine, caffeine, metronidazole, and amoxicillin had no clinically relevant interactions with pantoprazole.


Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.


There was also no interaction with concomitantly administered antacids.


There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including Protonix, and warfarin concomitantly [see Drug Interactions (7.2)].


Although no significant drug-drug interactions have been observed in clinical studies, the potential for significant drug-drug interactions with more than once daily dosing with high doses of pantoprazole has not been studied in poor metabolizers or individuals who are hepatically impaired.


Other Effects

In a clinical pharmacology study, pantoprazole 40 mg given orally once daily for 2 weeks had no effect on the levels of the following hormones: cortisol, testosterone, triiodothyronine (T3), thyroxine (T4), thyroid-stimulating hormone, thyronine-binding protein, parathyroid hormone, insulin, glucagon, renin, aldosterone, follicle-stimulating hormone, luteinizing hormone, prolactin and growth hormone.



Pharmacogenomics


CYP2C19 displays a known genetic polymorphism due to its deficiency in some subpopulations (e.g., approximately 3% of Caucasians and African-Americans and 17% to 23% of Asians are poor metabolizers). Although these subpopulations of pantoprazole poor metabolizers have elimination half-life values of 3.5 to 10.0 hours in adults, they still have minimal accumulation (≤ 23%) with once-daily dosing. For adult patients who are CYP2C19 poor metabolizers, no dosage adjustment is needed.


Similar to adults, pediatric patients who have the poor metabolizer genotype of CYP2C19 (CYP2C19 *2/*2) exhibited greater than a 6-fold increase in AUC compared to pediatric extensive (CYP2C19 *1/*1) and intermediate (CYP2C19 *1/*x) metabolizers. Poor metabolizers exhibited approximately 10-fold lower apparent oral clearance compared to extensive metabolizers.



Nonclinical Toxicology



Carcinogenesis, Mutagenesis, Impairment of Fertility


In a 24-month carcinogenicity study, Sprague-Dawley rats were treated orally with doses of 0.5 to 200 mg/kg/day, about 0.1 to 40 times the exposure on a body surface area basis of a 50-kg person dosed at 40 mg/day. In the gastric fundus, treatment at 0.5 to 200 mg/kg/day produced enterochromaffin-like (ECL) cell hyperplasia and benign and malignant neuroendocrine cell tumors in a dose-related manner. In the forestomach, treatment at 50 and 200 mg/kg/day (about 10 and 40 times the recommended human dose on a body surface area basis) produced benign squamous cell papillomas and malignant squamous cell carcinomas. Rare gastrointestinal tumors associated with pantoprazole treatment included an adenocarcinoma of the duodenum at 50 mg/kg/day and benign polyps and adenocarcinomas of the gastric fundus at 200 mg/kg/day. In the liver, treatment at 0.5 to 200 mg/kg/day produced dose-related increases in the incidences of hepatocellular adenomas and carcinomas. In the thyroid gland, treatment at 200 mg/kg/day produced increased incidences of follicular cell adenomas and carcinomas for both male and female rats.


In a 24-month carcinogenicity study, Fischer 344 rats were treated orally with doses of 5 to 50 mg/kg/day, approximately 1 to 10 times the recommended human dose based on body surface area. In the gastric fundus, treatment at 5 to 50 mg/kg/day produced enterochromaffin-like (ECL) cell hyperpl